The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed
Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A
diverse population of patients with type 1 diabetes will be studied. The study population
will have a large range for duration of diabetes and glycemic control, as measured by
glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior
diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous
Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)
This is a 6 month, multi-center, randomized, parallel, adaptive study in type 1 diabetes with
a 6 month continuation period. The study will have three periods:
Run-in Period: The run-in period can be up to 60 days during which time a blinded CGM
sensor will be worn for two weeks.
Study Period: There will be a 6 month randomized study period with two arms: The HCL
system and Control.
Continuation Period: There will be a 6 month continuation period during which time all
subjects will use the HCL system with Auto Mode.
Up to 1500 subjects will be enrolled in order to have 1120 subjects complete the study. Up to
70 investigational Centers in the US, Europe and Canada will be enrolled.
670G Insulin Pump,
Subject's Current Diabetes Therapy
Clinical Study Identifier
Last Modified on
15 October 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.